drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T-cell)
drug_description
Autologous BCMA-directed CAR T-cell therapy (CART-ddBCMA) using a D-domain CAR binder; after cyclophosphamide/fludarabine lymphodepletion, infused CAR-T cells recognize BCMA on malignant plasma cells and induce T-cell activation and cytotoxic killing.
nci_thesaurus_concept_id
C199003
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a BCMA-targeting chimeric antigen receptor (D-domain binder). Following cyclophosphamide/fludarabine lymphodepletion, the infused CAR T cells recognize BCMA on malignant plasma cells and trigger CAR-mediated T-cell activation, cytokine release, proliferation, and cytotoxic killing of BCMA-expressing myeloma cells.
drug_name
Anitocabtagene Autoleucel
nct_id_drug_ref
NCT06413498